Labcorp — Oct 24, 2024 release

l-Year 2024 Guidance: ◦ Revenue range of 6.6% to 7.3%; midpoint unchanged ◦ Adjusted EPS range of $14.30 to $14.70; midpoint down $0.10, due to the negative impact from weather of approximately $0.15 ◦ Free Cash Flow of $850 million to $980 million • Announced three new acquisitions/lab management agreements, and closed two acquisitions during the quarter that support growth initiatives BURLINGTON, N.C., October 24, 2024 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the third quarter ended September 30, 2024 and updated full-year guidance. “Labcorp achieved strong performance in Diagnostics and Biopharma Laboratories, including robust organic growth in the third quarter,” said Adam Schechter, chairman and CEO of Labcorp. “Our results demonstrate momentum in our core businesses as we introduced new tests, and extended our leadership position in specialty testing. We announced or completed several transactions with health systems and regional/local laboratories, which aligns with our acquisition strategy. We are on track to finish 2024 with strong growth as we focus on science, technology, and innovation and bring new tests and services to our customers.” 1 Labcorp advanced key growth initiatives that supported its strategy: • Announced an agreement to acquire select operating assets of Ballad Health’s outreach lab services, expanding the company’s labora